Herein, we developed PIPs targeting the EVI1-binding site within the GPR56 promoter and demonstrated significant efficacy of GPR56-PIP (56-1) treatment on the suppression of EVI1high AML cell growth both in vitro and in vivo. This evidence concerns the gene RUNX1 and acute myeloid leukemia.